Calgary, Canada

Kamal Elias Serhal

This inventor holds 13 USPTO granted patents and 6 published patent applications, plus 8 CIPO patents and 2 EPO patents. Top assignee: Nova Chemicals (International) S.a.. Active years: 2018-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kamal Elias Serhal. Retrieved from https://idiyas.com/inventor/kamal-elias-serhal

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2018-2024

Loading Chart...
Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: Inventor Kamal Elias Serhal - Pioneering Innovations in Calgary

Introduction: Kamal Elias Serhal is a distinguished inventor based in Calgary, Canada, known for his groundbreaking contributions to various technological fields.

Latest Patents: Kamal Elias Serhal holds several patents in the areas of renewable energy, sustainable agriculture, and advanced materials, showcasing his versatility and ingenuity.

Career Highlights: With a career spanning over two decades, Kamal Elias Serhal has worked tirelessly to develop solutions that address pressing global challenges, earning him recognition as a visionary in the innovation landscape.

Collaborations: Throughout his career, Kamal Elias Serhal has collaborated with leading research institutions, universities, and companies worldwide, fostering a culture of innovation and knowledge exchange.

Conclusion: Kamal Elias Serhal's passion for innovation and commitment to creating a better future through his inventions continue to inspire the next generation of inventors and entrepreneurs.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…